Scholar Rock Holding Co. (NASDAQ:SRRK) CEO Jay T. Backstrom Sells 22,308 Shares

Scholar Rock Holding Co. (NASDAQ:SRRK - Get Free Report) CEO Jay T. Backstrom sold 22,308 shares of the business's stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $44.20, for a total transaction of $986,013.60. Following the completion of the transaction, the chief executive officer now directly owns 330,363 shares of the company's stock, valued at $14,602,044.60. This trade represents a 6.33 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Scholar Rock Stock Performance

Shares of NASDAQ SRRK traded up $1.75 during midday trading on Tuesday, reaching $44.88. The company had a trading volume of 1,004,933 shares, compared to its average volume of 1,009,194. The stock has a market cap of $4.20 billion, a P/E ratio of -19.10 and a beta of 0.52. The company has a current ratio of 3.88, a quick ratio of 3.88 and a debt-to-equity ratio of 0.63. Scholar Rock Holding Co. has a 1 year low of $6.76 and a 1 year high of $46.19. The business's 50-day simple moving average is $39.58 and its 200 day simple moving average is $23.33.

Analysts Set New Price Targets

SRRK has been the subject of several recent research reports. Truist Financial boosted their price target on Scholar Rock from $36.00 to $45.00 and gave the stock a "buy" rating in a research report on Monday, November 25th. Wedbush reissued an "outperform" rating and set a $47.00 price target on shares of Scholar Rock in a research report on Thursday, January 9th. BMO Capital Markets raised their price target on shares of Scholar Rock from $34.00 to $38.00 and gave the company an "outperform" rating in a report on Friday, October 11th. HC Wainwright boosted their price objective on shares of Scholar Rock from $40.00 to $50.00 and gave the stock a "buy" rating in a research note on Tuesday, November 26th. Finally, JPMorgan Chase & Co. raised their target price on shares of Scholar Rock from $18.00 to $31.00 and gave the company an "overweight" rating in a research note on Monday, October 14th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $40.43.

Institutional Trading of Scholar Rock

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Clearbridge Investments LLC purchased a new position in shares of Scholar Rock in the second quarter worth about $6,223,000. Fisher Asset Management LLC raised its position in Scholar Rock by 593.6% during the 3rd quarter. Fisher Asset Management LLC now owns 734,019 shares of the company's stock worth $5,879,000 after buying an additional 628,186 shares during the last quarter. Millennium Management LLC lifted its stake in Scholar Rock by 159.2% during the 2nd quarter. Millennium Management LLC now owns 925,584 shares of the company's stock valued at $7,710,000 after acquiring an additional 568,512 shares during the period. Marshall Wace LLP lifted its stake in Scholar Rock by 1,051.3% during the 2nd quarter. Marshall Wace LLP now owns 487,285 shares of the company's stock valued at $4,059,000 after acquiring an additional 444,961 shares during the period. Finally, FMR LLC boosted its holdings in shares of Scholar Rock by 3.1% in the 3rd quarter. FMR LLC now owns 10,196,046 shares of the company's stock valued at $81,670,000 after acquiring an additional 308,813 shares during the last quarter. Institutional investors and hedge funds own 91.08% of the company's stock.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.